KEY POINTS
- This retrospective single-center study evaluated 276 patients with oligometastatic renal cell carcinoma, defined as five or fewer metastatic lesions, following nephrectomy between 2015 and 2023. 173 patients received complete metastasis-directed therapy (MDT) without initial systemic therapy, while 103 received systemic therapy with or without local treatment. Exact matching on six clinical and prognostic variables generated 72 matched pairs.
- Local therapy was predominantly surgical rather than radiation-based. Among the MDT-alone group, 78.6% underwent surgery alone, 12.1% received radiotherapy alone, and 9.2% received combined surgery and radiotherapy. In the systemic therapy group, 62.1% received tyrosine kinase inhibitor monotherapy, while only 29.1% received ICI-based combinations, limiting direct comparison with contemporary first-line immunotherapy regimens.
- After matching, five-year overall survival was 73.0% with MDT alone versus 58.6% with systemic therapy-based management, an absolute difference of 14.4 percentage points (HR 0.45, 95% CI 0.26–0.77; p=0.004). Five-year cancer-specific survival was also higher with MDT alone (83.7% vs 69.8%; HR 0.35, 95% CI 0.18–0.67; p=0.001).
- Despite the survival association, progression-free survival did not improve. Five-year PFS in the matched cohort was 16.3% with MDT alone versus 18.8% with systemic therapy (HR 1.11, 95% CI 0.77–1.61; p=0.579), and five-year distant metastasis-free survival was similarly comparable (20.7% vs 22.9%; HR 1.10; p=0.624). This discordance raises important uncertainty about whether the apparent survival advantage reflects treatment efficacy or unmeasured differences in disease biology and subsequent management.
- Complete local therapy provided substantial local disease control: five-year local progression-free survival was 80.2% with MDT alone versus 44.8% with systemic therapy-based management in matched patients (HR 0.28; p<0.001). However, this endpoint inherently favored the group in which all detectable lesions were treated locally, whereas many patients receiving systemic therapy did not undergo complete metastasis ablation.
- Systemic treatment could be deferred for prolonged periods in selected patients. Among all 173 MDT-alone patients, 86 (49.7%) eventually initiated systemic therapy, with a median observed interval of 22.9 months among those who started treatment. The cumulative incidence of systemic therapy initiation was 25.3% at two years and 48.6% at five years, while median systemic therapy-free survival was 53.0 months.
- Exploratory radiation-dose analysis showed no local failures among 12 patients whose irradiated lesions all received BED10 ≥80 Gy, compared with 3/14 failures (21.4%) when at least one lesion received a lower dose; all three occurred at bone sites. These numbers are too small to establish a dose threshold, and radiation-treated patients had more adverse disease characteristics. More broadly, patients selected for MDT initially had more solitary metastases and favorable-risk disease, while bone involvement remained imbalanced after matching; treatment-related toxicity and quality of life were not systematically evaluated.
CLINICAL TAKEAWAY
Complete local treatment may be a reasonable systemic therapy-deferring strategy for carefully selected patients with oligometastatic RCC, particularly those with limited, indolent disease amenable to eradication. However, this study does not establish superiority over contemporary ICI-based systemic therapy, and because most MDT patients underwent surgery, its survival findings should not be presented as direct evidence that SBRT improves overall survival.